Salim Syed
Stock Analyst at Mizuho
(1.80)
# 3,281
Out of 4,981 analysts
75
Total ratings
43.33%
Success rate
-0.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.97 | +610.66% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $51.13 | +64.29% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $144.86 | +16.66% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $276.39 | +1.31% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $114.55 | +2.14% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $6.97 | +215.64% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $32.18 | +406.53% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $12.12 | +48.51% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $19.96 | +70.34% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $56.26 | +75.97% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $51.21 | +3.50% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.29 | +1,527.91% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $21.80 | +65.18% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.97
Upside: +610.66%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $51.13
Upside: +64.29%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $144.86
Upside: +16.66%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $276.39
Upside: +1.31%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $114.55
Upside: +2.14%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $6.97
Upside: +215.64%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $32.18
Upside: +406.53%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $12.12
Upside: +48.51%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $19.96
Upside: +70.34%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $56.26
Upside: +75.97%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $51.21
Upside: +3.50%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.29
Upside: +1,527.91%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $21.80
Upside: +65.18%